Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med. 2 déc, vol.341, issue.23, pp.1725-1755, 1999. ,
Long-Term Complications in Renal Transplantation, J Am Soc Nephrol. 3 janv, vol.11, issue.3, pp.582-590, 2000. ,
Incidence of diagnosed deep vein thrombosis in the general population: systematic review, Eur J Vasc Endovasc Surg. janv, vol.25, issue.1, pp.1-5, 2003. ,
Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States, Am J Kidney Dis. janv, vol.43, issue.1, pp.120-150, 2004. ,
Epidemiology of venous thromboembolism, Nat Rev Cardiol. août, vol.12, issue.8, pp.464-74, 2015. ,
Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study, Ann Intern Med. 16 févr, vol.152, issue.4, pp.218-242, 2010. ,
Pathophysiology of venous thrombosis, Thromb Res, vol.123, pp.30-34, 2009. ,
Hypercoagulability in Kidney Transplant Recipients, Transplantation. avr, vol.100, issue.4, pp.719-745, 2016. ,
Acquired hypercoagulable state in renal transplant recipients, Thromb Haemost. avr, vol.91, issue.4, pp.646-54, 2004. ,
, médecine/sciences. déc, vol.26, issue.12, pp.1056-60, 2010.
,
,
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data, BMJ, vol.349, p.6679, 2014. ,
, Résumé des caractéristiques du produit -CERTICAN 0,1 mg
Treatment with everolimus is associated with a procoagulant state, Thromb Res. août, vol.132, issue.2, pp.307-318, 2013. ,
Enhancement of human platelet aggregation and secretion induced by rapamycin, Nephrol Dial Transplant. déc, vol.13, issue.12, pp.3153-3162, 1998. ,
Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients, Transplantation. 27 juill, vol.76, issue.2, pp.318-341, 2003. ,
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study, Am J Transplant. janv, vol.15, issue.1, pp.119-147, 2015. ,
Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial, Am J Transplant, vol.17, issue.4, pp.1020-1050, 2017. ,
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study, Transplantation. 27 août, vol.92, issue.4, pp.410-418, 2011. ,
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, N Engl J Med. 20 déc, vol.357, issue.25, pp.2562-75, 2007. ,
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial, Transplantation. 27 janv, vol.87, issue.2, pp.233-275, 2009. ,
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, J Am Soc Nephrol JASN. juill, vol.29, issue.7, pp.1979-91, 2018. ,
Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not longterm recovery in experimental thrombotic microangiopathy, Nephrol Dial Transplant, vol.21, issue.10, pp.2724-2759, 2006. ,
Sirolimusinduced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys, Am J Transplant. oct, vol.5, issue.10, pp.2441-2448, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00086023
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?, Am J Transplant. mars, vol.3, issue.3, pp.324-331, 2003. ,
Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation, Transplant Proc. sept, vol.46, issue.7, pp.2263-2271, 2014. ,
Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation, Transplantation. 15 avr, vol.95, issue.7, pp.933-975, 2013. ,
Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine, Clin Transplant. avr, vol.27, issue.2, pp.217-243, 2013. ,
Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial, Transplantation. 15 mars, vol.93, issue.5, pp.503-511, 2012. ,
Threeyear Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study, Transplantation. juill, vol.99, issue.7, pp.1455-62, 2015. ,
retour d'information sur le PRAC de juin 2017 -Point d'information -ANSM : Agence nationale de sécurité du médicament et des produits de santé ,
Sirolimus use and incidence of venous thromboembolism in cardiac transplant recipients, Clin Transplant. déc, vol.26, issue.6, pp.953-962, 2012. ,
Venous thromboembolism in heart transplant recipients: Incidence, recurrence and predisposing factors, J Heart Lung Transplant. 1 févr, vol.34, issue.2, pp.167-74, 2015. ,
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization, N Engl J Med. 6 juin, vol.346, issue.23, pp.1773-80, 2002. ,
, Venous Thromboembolic Disease after Lung Transplantation: Special Focus on Sirolimus. Open Transplant J [Internet, vol.18, issue.2010
Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation, J Heart Lung Transplant. févr, vol.30, issue.2, pp.175-81, 2011. ,
A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications, Transplantation. 27 juill, vol.78, issue.2, pp.264-272, 2004. ,
Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients, Transpl Int. févr, vol.23, issue.2, pp.155-68, 2010. ,
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects, Transplantation. 15 mai, vol.83, issue.9, pp.1162-1170, 2007. ,
, Cytomegalovirusassociated venous thromboembolism in renal transplant recipients: a report of 7 cases, vol.77, pp.597-606, 2004.
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry, Haematologica. févr, vol.93, issue.2, pp.273-281, 2008. ,
Malignancies, prothrombotic mutations, and the risk of venous thrombosis, JAMA. 9 févr, vol.293, issue.6, pp.715-737, 2005. ,
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study, Arch Intern Med. 10 juin, vol.162, issue.11, pp.1245-1253, 2002. ,
Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, Br J Cancer. 28 sept, vol.103, issue.7, pp.947-53, 1997. ,
Epidemiology of cancerassociated venous thrombosis, Blood. 5 sept, vol.122, issue.10, pp.1712-1735, 2013. ,
Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch Intern Med. 27 févr, vol.166, issue.4, pp.458-64, 2006. ,
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation, J Am Soc Nephrol JASN. févr, vol.17, issue.2, pp.581-590, 2006. ,
Post-transplant de novo malignancies in renal transplant recipients: the past and present, Transpl Int Off J Eur Soc Organ Transplant. août, vol.19, issue.8, pp.607-627, 2006. ,
Sirolimus and secondary skin-cancer prevention in kidney transplantation, N Engl J Med. 26 juill, vol.367, issue.4, pp.329-368, 2012. ,
Sirolimus for Kaposi's sarcoma in renal-transplant recipients, N Engl J Med. 31 mars, vol.352, issue.13, pp.1317-1340, 2005. ,
Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial, Am J Transplant. juin, vol.10, issue.6, pp.1385-93, 2010. ,
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial, Transplantation. 15 août, vol.92, issue.3, pp.303-313, 2011. ,
, Fiche info -AFINITOR 10 mg, comprimé -Base de données publique des médicaments
,
Renal allograft thrombosis, Nephrol Dial Transplant. 1 mai, vol.24, issue.5, pp.1388-93, 2009. ,
Transplant Renal Vein Thrombosis, Exp Clin Transplant. avr, vol.15, issue.2, pp.123-132, 2017. ,
Objective: Everolimus is an immunosupressive agent used in kidney transplantation. its use is associated with a biological procoagulant state. We studied the potential association of everolimus with the risk of veinous thromboembolic events (VTE), Nephrol Dial Transplant Abstract ,
, We evaluated two cohorts, one treated with everolimus (« Imtor + » cohort) and the other without (control group). The diagnosis of VTE was assessed by hospitalisation records. The monitoring period began at the introduction of everolimus for the first cohort, and at the date of kidney transplantation for the second and finished at the last medical contact for both, Study design: We conducted a monocentric retrospective study in renal transplant recipients in Amiens, 2017.
, Results: There were 117 patients in the « Imtor + » cohort and 234 patients in the control cohort. VTE was more fréquent in the first group (12,8% versus 5,9%; p = 0,028). In a multivarate model, VTE was independently associated with BMI (HR = 1,079
, 044) Conclusion: The use of everolimus is independently associated with VTE, p.0
, Keywords: venous thromboembolism, everolimus, kidney transplantation, retrospective study, adverse effects